The company's financial position is increasingly precarious, characterized by a negative equity balance of $38.1M and a critically low current ratio of 0.15.
| Total Current Assets | 12.32M | 20.56M | 19.79M | 33.5M | 59.1M | 72.16M | 36.81M | 24.71K |
| Cash & Short-Term Investments | 6.17M | 738K | 227K | 13.97M | 37.24M | 54.31M | 28.13M | 24.71K |
| Cash Only | 6.17M | 738K | 227K | 13.97M | 37.24M | 54.31M | 28.13M | 24.71K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 4.65M | 13.56M | 12.12M | 6.97M | 5.23M | 6.55M | 3.08M | 3.92M |
| Days Sales Outstanding | 63.97 | 91.26 | 194.24 | 141.45 | 89.53 | 167.44 | 53.13 | 81.49 |
| Inventory | 571K | 5.41M | 5.75M | 5.31M | 9.55M | 3.85M | 3.23M | 3.54M |
| Days Inventory Outstanding | 32.76 | 131.72 | 131.11 | 98.52 | 361.07 | 284.93 | 186.54 | 196.89 |
| Other Current Assets | 222K | 857K | 0 | 1.05M | 2K | 873K | 480K | 1.49M |
| Total Non-Current Assets | 95.01M | 112.12M | 124.1M | 367.56M | 355.03M | 358.85M | 484.69M | 532.17M |
| Property, Plant & Equipment | 66.52M | 72.43M | 78.82M | 88.72M | 90.63M | 90.08M | 66.39M | 4.01M |
| Fixed Asset Turnover | 0.40x | 0.75x | 0.29x | 0.20x | 0.24x | 0.16x | 0.32x | 4.38x |
| Goodwill | 7.35M | 7.35M | 7.35M | 119.69M | 123.3M | 123.3M | 127.07M | 130.64M |
| Intangible Assets | 7.76M | 9.25M | 11M | 120.99M | 123.19M | 125.38M | 271.47M | 393.71M |
| Long-Term Investments | 0 | 10.24M | 9.94M | 14.84M | 14.84M | 15.2M | 291M | 0 |
| Other Non-Current Assets | 13.39M | 12.86M | 26.93M | 23.32M | 3.08M | 4.89M | -271.24M | 3.81M |
| Total Assets | 107.33M | 132.68M | 143.89M | 401.07M | 414.13M | 431.01M | 521.5M | 24.71K |
| Asset Turnover | 0.25x | 0.41x | 0.16x | 0.04x | 0.05x | 0.03x | 0.04x | 710.49x |
| Asset Growth % | -19.11% | -7.79% | -64.12% | -3.15% | -3.92% | -17.35% | 2110617.61% | - |
| Total Current Liabilities | 80.76M | 53.68M | 67.3M | 62.09M | 26.23M | 26.68M | 20.64M | 150.56K |
| Accounts Payable | 26.42M | 23.3M | 14.14M | 5.81M | 9.32M | 5.39M | 18.88K | 5.27M |
| Days Payables Outstanding | 1.52K | 567.29 | 322.34 | 107.84 | 352.3 | 398.89 | 1.09 | 293.34 |
| Short-Term Debt | 14M | 6.36M | 39.24M | 37.6M | 3.05M | 3.01M | 0 | 0 |
| Deferred Revenue (Current) | 5.25M | 3.53M | 2.83M | 2.27M | 2.2M | 5.12M | 0 | 0 |
| Other Current Liabilities | 6.92M | 1.6M | 8.07M | 13.83M | 7.83M | 8.17M | 11.23M | -10.74M |
| Current Ratio | 0.15x | 0.38x | 0.29x | 0.54x | 2.25x | 2.70x | 1.78x | 0.16x |
| Quick Ratio | 0.15x | 0.28x | 0.21x | 0.45x | 1.89x | 2.56x | 1.63x | -23.32x |
| Cash Conversion Cycle | -1.42K | -344.31 | 3.01 | 132.13 | 98.3 | 53.47 | 238.58 | -14.95 |
| Total Non-Current Liabilities | 64.63M | 70.17M | 35.63M | 140.08M | 288.48M | 385.62M | 363M | 0 |
| Long-Term Debt | 0 | 35.93M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 26.9M | 26.55M | 26.18M | 27.98M | 28.09M | 27.63M | 28.06M | 0 |
| Deferred Tax Liabilities | 12K | 9K | 9K | 9K | 10K | 7K | 0 | 0 |
| Other Non-Current Liabilities | 34.92M | 4.96M | 6.26M | 109.86M | 258.52M | 350.36M | 334.94M | 0 |
| Total Liabilities | 145.39M | 123.84M | 102.93M | 202.16M | 314.71M | 412.3M | 383.63M | 150.56K |
| Total Debt | 40.9M | 68.84M | 65.42M | 65.59M | 31.14M | 30.64M | 28.06M | 150K |
| Net Debt | 34.73M | 68.1M | 65.19M | 51.62M | -6.1M | -23.67M | -66K | 125.29K |
| Debt / Equity | - | 7.79x | 1.60x | 0.33x | 0.31x | 1.64x | 0.20x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.03x |
| Interest Coverage | -12.58x | -8.24x | -64.10x | - | -30.57x | -89.46x | - | - |
| Total Equity | -38.06M | 8.84M | 40.96M | 198.9M | 99.42M | 18.71M | 137.86M | -125.85K |
| Equity Growth % | -530.71% | -78.43% | -79.41% | 100.07% | 431.28% | -86.43% | 109647.31% | - |
| Book Value per Share | -1.49 | 0.40 | 2.30 | 13.28 | 7.81 | 10.16 | 57.75 | -0.04 |
| Total Shareholders' Equity | -38.06M | 8.84M | 40.96M | 198.9M | 99.42M | 18.71M | 137.86M | -125.85K |
| Common Stock | 3K | 2K | 19K | 15K | 12K | 1K | 1K | 863 |
| Retained Earnings | -991.48M | -899.68M | -841.79M | -645.5M | -663.68M | -563.56M | -355.33M | -1.1K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -256K | 0 | 0 |
| Accumulated OCI | 0 | -5K | 0 | 9K | 0 | 0 | 0 | -149.75K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and insolvency
As reported in recent financial filings, Celularity's equity position has deteriorated into a deficit of $38.1M by 2025Q4, reflecting a persistent trend of value destruction that signals a weakening balance sheet trajectory and significant doubt regarding the company's long-term financial viability.
The shift from positive equity to a substantial deficit indicates that cumulative losses have entirely eroded the company's net worth. This trajectory suggests that the business model is currently unable to generate sufficient returns to offset its operational burn, leaving shareholders exposed to potential total loss.
Based on the company's 2025Q4 balance sheet, total debt stands at $40.9M, which, when viewed against a negative equity position, highlights a precarious leverage profile that severely limits the company's financial flexibility and increases the risk of default in the near term.
The presence of significant debt on a balance sheet with negative equity suggests that the company is relying on external financing to survive rather than operational cash flow. Investors should monitor the maturity profile of these obligations, as the current liquidity position appears insufficient to support meaningful debt service.
According to the latest quarterly data, the current ratio has plummeted to 0.15, indicating that Celularity possesses only a fraction of the liquid assets required to cover its short-term liabilities, which underscores an extreme liquidity risk that warrants immediate investor caution.
A current ratio of 0.15 is indicative of a company facing a severe working capital crisis where current assets are insufficient to meet immediate obligations. This suggests that the firm may be forced to pursue highly dilutive financing or asset liquidations to maintain basic operations.
As reported in financial statements, the company maintains $66.5M in net property, plant, and equipment, which represents the bulk of its asset base and suggests that the firm's value is tied to specialized manufacturing infrastructure that may lack liquidity in a distress scenario.
The concentration of assets in specialized PPE implies that the company's ability to recover value is highly dependent on the successful commercialization of its clinical pipeline. If these assets fail to generate revenue, the risk of significant impairment charges appears high, further pressuring the already negative equity position.
Quick answers to the most common questions about buying CELU stock.
As of 2025, Celularity Inc. (CELU) had total assets of $107.3M including $12.3M in current assets.
Celularity Inc. (CELU) carries total debt of $40.9M, offset by $6.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Celularity Inc. (CELU) has total shareholders' equity (book value) of $-38.1M ($-1.49 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Celularity Inc. (CELU) reported a current ratio of 0.15x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.